Find out all news, publications, posters and events
related to microbiome and EMIH (formerly known as APM) activities
News
08/11/2024
EMIH is a partner of the 8th edition of the Microbiota and Health Day organized by Lyonbiopôle Auvergne-Rhône-Alpes.
> READ
EMIH is a partner of the 8th edition of the Microbiota and Health Day organized by Lyonbiopôle Auvergne-Rhône-Alpes.
> READ
News
25/09/2024
European Microbiome Innovation for Health and Microbiome Therapeutics Innovation Group join forces with Microbiome Times on important deal-making event, taking place Brussels 2025
> READ
European Microbiome Innovation for Health and Microbiome Therapeutics Innovation Group join forces with Microbiome Times on important deal-making event, taking place Brussels 2025
> READ
News
23/09/2024
European Microbiome Innovation for Health and Microbiome Therapeutics Innovation Group Announce New Collaboration Agreement
> READ
European Microbiome Innovation for Health and Microbiome Therapeutics Innovation Group Announce New Collaboration Agreement
> READ
News
14/05/2024
The Alliance Promotion Microbiote is becoming the European Microbiome Innovation for Health: a major step towards structuring the European microbiome excellence sector
> READ
The Alliance Promotion Microbiote is becoming the European Microbiome Innovation for Health: a major step towards structuring the European microbiome excellence sector
> READ
News
News
09/11/2023
Alliance Promotion Microbiote To Welcome Ferring Pharmaceuticals, Pelican Health and Polepharma as New Members
> READ
Alliance Promotion Microbiote To Welcome Ferring Pharmaceuticals, Pelican Health and Polepharma as New Members
> READ
News
24/08/2023
Alliance Promotion Microbiote applauds the new legislation securing stool collection in France
> READ
Alliance Promotion Microbiote applauds the new legislation securing stool collection in France
> READ
News
26/04/2023
MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease
> READ
MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease
> READ
News
Events
News
16/01/2023
Everimmune launches Phase I clinical trial for its oncobiotic drug candidate in lung and kidney cancer
> READ
Everimmune launches Phase I clinical trial for its oncobiotic drug candidate in lung and kidney cancer
> READ
News
News
29/11/2022
TargEDys and SymbioPharm enter an exclusive partnership to launch SymbioLife® Satylia® in Germany
> READ
TargEDys and SymbioPharm enter an exclusive partnership to launch SymbioLife® Satylia® in Germany
> READ